Billionaire Profile
R
Global Rank
#2065

Image: Church of Scotland Westminster Assembly (1643-1652) | Public domain | via Wikimedia Commons

Randal J. Kirk

CEO, Pharmaceuticals
UNITED STATES
Real-Time Net Worth
$2.034B
Estimated based on Pharmaceuticals stock value as of April 21, 2026
+0.75% (24h)
Age
72
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
UNITED STATES

Biography

Randal J. Kirk, a self-made billionaire, is a prominent figure in the pharmaceutical and biotechnology industries. His wealth source primarily stems from his investments in these sectors. His career includes founding and selling successful pharmaceutical companies, such as New River Pharmaceuticals, and his current role as the Executive Chairman of Third Security. Kirk, 72, is known for his strategic investments and innovative approaches to biotechnology, including his work in synthetic biology and genetic engineering. He is recognized for his contributions to the industry, and he holds a Doctor of Jurisprudence from the University of Virginia. As of March 2026, his net worth is estimated at $2.0 billion.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/21/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Randal J. Kirk was born in Pleasanton, California, on March 1, 1954. As the son of a U.S. Air Force master sergeant, his family relocated frequently, eventually settling in Virginia and Florida. Kirk's early life included an entrepreneurial spirit, demonstrated by selling greeting cards door-to-door at age nine with significant success. He earned a Bachelor of Arts in Economics from Radford University in 1976, followed by a Juris Doctor from the University of Virginia in 1979. He started his career as an attorney, practicing law in Bland, Virginia, from 1980 to 1990.

Rise to Success

In 1983, Kirk co-founded General Injectables and Vaccines, which he later sold. His most significant success came with New River Pharmaceuticals, which he founded in 1996 and took public in 2004. Kirk served as chairman and CEO and sold the company to Shire in 2007 for $2.6 billion, earning over $1 billion personally. In 1999, Kirk founded Third Security, LLC, a life sciences investment firm, where he currently serves as Senior Managing Director, CEO, and Chairman. From 2008 to 2020, he was the Chairman and CEO of Intrexon, a biotechnology company. In 2020, Intrexon adopted the name Precigen, and Kirk stepped down as CEO while remaining as Executive Chairman.

Key Business Strategies

Kirk's success is attributed to a focus on high-risk, high-reward investments and staying invested in companies until products reached the market. His strategy involved betting on a few small companies and staying the course. Kirk is known for his innovative approach to biotechnology, including genetic engineering and synthetic biology. His investments have made waves for innovative products, like apples that never brown and a genetically modified species of salmon.

Philanthropy

Kirk's philanthropy includes a $1 million donation to Radford University, which established the Zylphia Shu-En Kirk Endowment. He served on the boards of the Radford University Foundation and the University's Board of Visitors. Kirk has also donated to political causes and considers himself an independent. His philanthropy score is 1 on a scale of 1–5, indicating limited major charitable giving relative to his wealth.

Career Milestones

1980

Admitted to the Bar

Became the only attorney in Bland, Virginia.

1983

Co-founded General Injectables and Vaccines

Founded the next-day pharmaceutical distributor.

1996

Founded New River Pharmaceuticals

Served as chairman and CEO.

1999

Founded Third Security, LLC

Life sciences investment firm.

2008

Chairman of Intrexon

Became chairman of Intrexon's board.

2020

Stepped down as CEO of Precigen

Remained as Executive Chairman.

Philanthropy & Social Impact

Education

Zylphia Shu-En Kirk Endowment

$1M

Donation to Radford University.

Business Philosophy & Leadership

Notable Quotes

"Every man will yield the results he deserves."